The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Trial Title: The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

NCT ID: NCT06242392

Condition: Ovarian Neoplasms

Conditions: Official terms:
Ovarian Neoplasms

Conditions: Keywords:
Ovarian Neoplasms
homologous recombination deficiency
prognosis
Cost-effectiveness analysis

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Cross-Sectional

Intervention:

Intervention type: Genetic
Intervention name: homologous recombination deficiency
Description: Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.
Arm group label: effective group
Arm group label: ineffective group

Summary: Clinicopathological data were collected from ovarian cancer patients treated with PARP inhibitors, with follow-up imaging conducted before and after treatment. The efficacy was evaluated according to RECIST criteria, comparing the correlation between different HRD statuses and the efficacy of PARP inhibitors in ovarian cancer.

Criteria for eligibility:

Study pop:
Patients with Ovarian Cancer who were treated from June 2020 to December 2026 and met the above inclusion and exclusion criteria

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Patients diagnosed with ovarian cancer (any histological type) and possessing complete pathological hematoxylin and eosin (HE) stained slides and paraffin-embedded tissue blocks. - Patients must be 18 years of age or older. - Patients should not have concurrent multiple primary cancers. - Patients must undergo an MRI or CT scan prior to starting treatment. - According to RECIST (Response Evaluation Criteria In Solid Tumors) criteria, patients must have at least one measurable lesion. - Participants must provide informed consent, voluntarily cooperate with clinical follow-up, and sign an informed consent form. Exclusion Criteria: - Patients who do not have accessible tumor tissue required for Homologous Recombination Deficiency (HRD) testing. - Patients whose clinical records are incomplete, making it impossible to effectively compare treatment efficacy. - Patients who are lost to follow-up and for whom subsequent treatment outcomes cannot be tracked.

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: January 31, 2024

Completion date: July 1, 2026

Lead sponsor:
Agency: Fujian Cancer Hospital
Agency class: Other

Collaborator:
Agency: Fujian Provincial Hospital
Agency class: Other

Source: Fujian Cancer Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06242392